LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Syndax Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

16.23 2.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

15.48

Massimo

16.28

Metriche Chiave

By Trading Economics

Entrata

13M

-72M

Vendite

18M

38M

Margine di Profitto

-189.28

Dipendenti

270

EBITDA

20M

-64M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+111.99% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

456M

1.3B

Apertura precedente

13.9

Chiusura precedente

16.23

Notizie sul Sentiment di mercato

By Acuity

15%

85%

13 / 372 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Syndax Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 ago 2025, 22:51 UTC

Utili

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Rev $4.01B

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H Adj EPS $1.84

27 ago 2025, 23:57 UTC

Utili

Trip.com Group 1H EPS $1.82

27 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 ago 2025, 23:39 UTC

Utili

Correction to Nvidia Earnings Article -- WSJ

27 ago 2025, 22:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 ago 2025, 22:59 UTC

Discorsi di Mercato

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 ago 2025, 22:58 UTC

Utili

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 ago 2025, 22:57 UTC

Utili

South32 FY Free Cash Flow $192 Million

27 ago 2025, 22:56 UTC

Utili

South32 FY Total Capital Expenditure $1.35 Billion

27 ago 2025, 22:56 UTC

Utili

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 ago 2025, 22:55 UTC

Utili

South32 Net Cash $123 Million at June 30

27 ago 2025, 22:54 UTC

Utili

South32: Focused on Maintaining Strong Operating Momentum

27 ago 2025, 22:53 UTC

Utili

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 ago 2025, 22:53 UTC

Utili

South32 Extends Capital Management Program for 12 Months

27 ago 2025, 22:52 UTC

Utili

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 ago 2025, 22:51 UTC

Utili

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 ago 2025, 22:50 UTC

Utili

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 ago 2025, 22:50 UTC

Utili

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 ago 2025, 22:45 UTC

Utili

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 ago 2025, 22:44 UTC

Utili

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 ago 2025, 22:43 UTC

Utili

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 ago 2025, 22:43 UTC

Utili

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 ago 2025, 22:42 UTC

Utili

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources Net Debt $123 Million at June 30

27 ago 2025, 22:40 UTC

Utili

Sandfire Resources FY Underlying Ebitda $527.7 Million

Confronto tra pari

Modifica del prezzo

Syndax Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

111.99% in crescita

Previsioni per 12 mesi

Media 33.6 USD  111.99%

Alto 56 USD

Basso 17 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Syndax Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

10

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.91 / 14.15Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

13 / 372 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.